116 related articles for article (PubMed ID: 2234543)
1. Neurotoxicology dose/response assessment for several cholinesterase inhibitors: use of uncertainty factors.
Raffaele KC; Rees C
Neurotoxicology; 1990; 11(2):237-56. PubMed ID: 2234543
[TBL] [Abstract][Full Text] [Related]
2. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
3. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
4. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
5. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
7. A review of the reference dose for chlorpyrifos.
Zhao Q; Dourson M; Gadagbui B
Regul Toxicol Pharmacol; 2006 Mar; 44(2):111-24. PubMed ID: 16360256
[TBL] [Abstract][Full Text] [Related]
8. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
9. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
10. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity modeling for risk assessment.
Kodell RL; Chen JJ; Gaylor DW
Regul Toxicol Pharmacol; 1995 Aug; 22(1):24-9. PubMed ID: 7494899
[TBL] [Abstract][Full Text] [Related]
12. Quantitative approaches to human risk assessment for noncancer health effects.
Kimmel CA
Neurotoxicology; 1990; 11(2):189-98. PubMed ID: 2234540
[TBL] [Abstract][Full Text] [Related]
13. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
14. Procedures for calculating benchmark doses for health risk assessment.
Gaylor D; Ryan L; Krewski D; Zhu Y
Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dose/time/response relationships for chronic toxic effects: the case of acrylamide.
Hattis D; Shapiro K
Neurotoxicology; 1990; 11(2):219-36. PubMed ID: 2234542
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicology risk assessment guidelines: developmental neurotoxicology.
Tilson HA
Neurotoxicology; 2000; 21(1-2):189-94. PubMed ID: 10794399
[TBL] [Abstract][Full Text] [Related]
17. Towards quantitative risk assessment for neurotoxicity.
Wyzga RE
Neurotoxicology; 1990; 11(2):199-207. PubMed ID: 2234541
[TBL] [Abstract][Full Text] [Related]
18. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
Renwick AG; Walker R
Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
[TBL] [Abstract][Full Text] [Related]
19. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics.
Int J Toxicol; 2005; 24 Suppl 2():21-50. PubMed ID: 16154914
[TBL] [Abstract][Full Text] [Related]
20. Evolution and current status of neurotoxicity risk assessment.
Tilson HA
Drug Metab Rev; 1996; 28(1-2):121-39. PubMed ID: 8744593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
